Noxafil Schering-Plough Corporation - Treatment for Prevention of Invasive Fungal InfectionsNoxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Posted: September 2006
- FDA Approves Merck’s Noxafil (posaconazole) Injection - March 14, 2014
- FDA Approves Merck’s Noxafil Delayed-Release Tablets - November 26, 2013
- Schering-Plough Reports Posaconazole NDA Accepted for FDA Review - July 13, 2004